Lyophilized amniotic membrane graft for primary pterygium surgery: preliminary results

Cell Tissue Bank. 2022 Jun;23(2):401-406. doi: 10.1007/s10561-021-09955-3. Epub 2021 Oct 10.

Abstract

The aim of this study was to investigate the tolerability, safety and efficacy of new lyophilized amniotic membrane (LAM) presentation for ocular use. A prospective case-series cohort of four patients with primary nasal pterygium which undergone excision and LAM implantation was evaluated for complications and clinical outcomes. Surgical manipulation of LAM was also assessed. LAM was stiff and easy to manipulate as well as no tearing occurred during surgery or suturing. Ocular comfort was checked and similar among those patients with LAM glued or sutured. After 12 months, there were no issues about tolerability or adverse events. Lower cosmetic outcomes (recurrence) were stated in 3 patients. Our study showed that LAM could be an effective alternative to cryopreserved amniotic membrane for graft after pterygium excision surgery. Its main advantage, storage at room temperature, can make it of immediate availability. Further studies comparing clinical outcomes of pterygium surgery with cryopreserved amniotic membrane versus LAM would confirm the benefits of the last.

Keywords: Cryopreserved amniotic membrane; Eye bank; Lyophilized amniotic membrane; Pterygium; Recurrence; Tissue bank.

MeSH terms

  • Amnion / transplantation
  • Conjunctiva / abnormalities
  • Conjunctiva / transplantation
  • Follow-Up Studies
  • Humans
  • Pterygium* / surgery
  • Recurrence
  • Transplantation, Autologous
  • Treatment Outcome

Supplementary concepts

  • Pterygium Of Conjunctiva And Cornea